12 results about "Controlled-Release Formulations" patented technology

The invention discloses a CaCO3-based validamycin controlled release preparation and a preparation method thereof, and the preparation method comprises the following steps: taking glucose, amino acid and water as raw materials, reacting under a microwave heating condition, and standing to obtain carbon dots; wherein the amino acid is one or a mixture of more of lysine, histidine and arginine; the preparation method comprises the following steps: mixing validamycin, water and calcium acetate, stirring, adding carbon dots, and stirring to obtain a validamycin / carbon dot mixed solution; and adding a sodium carbonate aqueous solution into the validamycin / carbon dot mixed solution, stirring, standing, and drying the obtained precipitate to obtain the CaCO3-based validamycin controlled release preparation. The controlled release preparation has the characteristics of high drug loading rate, controllable drug release, simple preparation process and the like, and provides a new strategy for developing CaCO3-based nano pesticides.

The present invention relates to tablet composition for oral administration of Ruxolitinib phosphate, with a combination of low viscosity HPMC and high viscosity HPMC.

The application belongs to the field of drug design, and discloses a preparation method of oral solid controlled-release preparation based on micro-droplet spraying, comprising the following steps: S1, separating and designing the distribution of active pharmaceutical ingredients and pharmaceutical excipients in the preparation; S2, recombining the ingredient information after the separation and design; S3, converting the ingredient distribution information after the combination into a slice recognizable by a 3D printing device; S4, printing by using a double-channel micro-droplet spraying 3D printer; and S5, using a powder material to receive the ingredients sprayed by the printer, so as to bond and form a solid preparation. The concentration gradient function defined by the application defines the concentration distribution method of the active pharmaceutical ingredients in the preparation, and solves the problem that the controlled-release preparation cannot achieve ideal controlled-release effect in principle; the 3D printing of the oral solid controlled-release preparation by using the double-channel micro-droplet spraying principle can change the existing preparation process mode, and can prepare the oral solid controlled-release preparation meeting the functional design requirements.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa.

The application relates to the technical field of biological medicine manufacturing, and discloses a controlled-release type preparation composition for realizing ovary function recovery, which comprises a core active unit, a moisturizing slow-release unit and a plant extract component. The core active unit is an anisotropic core-shell structure microcapsule with asymmetric charge distribution, which is composed of chitosan, polyglutamic acid and an internal compound, and a layer of outwardly radiating carboxyl brush-shaped molecular chain is distributed on the surface of the core active unit. The moisturizing slow-release unit comprises a polymer skeleton formed by rosmarinic acid and hyaluronic acid, and the polymer skeleton internally occludes elemene. The application utilizes a kinetic restriction mechanism to construct an anisotropic surface layer topology, avoids mucus protein adsorption, induces anti-inflammatory immune regulation by physically adapting mucosal receptors, the moisturizing slow-release unit firstly constructs a physical barrier to repair damage, and the core active unit is used to realize component graded controlled release.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cilostazol controlled-release preparation and a preparation method thereof. The preparation is based on a composite carrier composed of mesoporous silica and low-substituted hydroxy propyl cellulose, the cilostazol is highly dispersed in the composite carrier in an amorphous state through combination of ball milling pretreatment and a high-temperature fluidized bed melt dispersion process, and a final tablet is obtained through tabletting by adopting a step-by-step design of internally and externally adding a disintegrating agent. The dissolution rate of the cilostazol preparation prepared by the invention is greater than or equal to 80% within 15 minutes and greater than or equal to 95% within 30 minutes, so that rapid and stable drug release is realized, and the risk of burst release of the drug and adverse reaction caused by fluctuation of blood concentration are effectively reduced; and the preparation shows excellent stability, and an acceleration test (6 months) result shows that the increase of related substances of the preparation is less than or equal to 0.5%, the change rate of the dissolution rate is less than or equal to 3%, and the consistency and reliability of the curative effect in the clinical medication process can be effectively guaranteed.

To provide a solid preparation for a highly lipophilic physiologically active substance such as cannabinoid which releases the physiologically active substance and can be prepared by a simple method.SOLUTION: The present invention relates to a product for the release of a highly lipophilic bioactive substance comprising a core and a coating on the core, wherein the coating comprises one or more highly lipophilic bioactive substances, one or more water-soluble film-forming agents and up to 20% by weight, based on the weight of all components, of other excipients.SELECTED DRAWING: Figure 1

Providing a controlled-release formulation containing dorotaberine or its salts, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. [Solution] The present invention provides a controlled-release formulation containing dorotaberine or a salt thereof, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. The present invention provides a once- or twice-daily controlled-release formulation of dorotaberine or a salt thereof that avoids fluctuations in plasma levels, reduces pill burden and side effects through a simplified dosing schedule, and consequently improves patient compliance. The present invention also provides a method for preparing a controlled-release formulation of dorotaberine or a salt thereof. The present invention further provides a controlled-release formulation of dorotaberine or a salt thereof for the treatment of at least one symptom of gastrointestinal, biliary, urinary, and gynecological disorders characterized by a spastic state of smooth muscle in a subject.

The present invention relates to a product for the release of highly lipophilic bioactive substances, comprising a core and a coating on the core, wherein the coating comprises one or more highly lipophilic bioactive substances, one or more water-soluble film-forming agents, and up to 20% by weight of other excipients based on the weight of all ingredients.

It is proposed that dissipation of relative benefit during long-term treatment is due to long-term tolerance to stimulant medications. To improve adherence and persistence of medication use, it is advantageous to develop medications that are not undermined by long-term tolerance. Disclosed herein in certain implementations are methods for the prevention of accumulated tolerance to stimulant medication for the treatment of ADHD based on two principles: (a) retaining the initial immediate-release component of controlled-release formulations, and (b) replacing the subsequent sustained-release component (i.e., an ascending delivery of stimulant medication to counteract acute tolerance) with a controlled-release component designed to prevent carry-over effects on background tonic dopamine.